Hormonal
Triple hormone receptor agonist retatrutide (1-12 mg weekly) significantly reduces liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), achieving near-maximal reduction (~80%) at 24 weeks with high doses (8-12 mg).
For patients with MASLD, high-dose retatrutide (8-12 mg weekly) offers a highly effective treatment to significantly reduce liver fat, often normalizing it within 24 weeks. This hormonal intervention addresses the root metabolic drivers of liver fat accumulation more potently than current GLP-1 mono-agonists.
The mean relative change from baseline in LF at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg) and +0.3% (placebo) (all P < 0.001 versus placebo).
Why this rating
Randomized, double-blind, placebo-controlled phase 2a trial with statistically significant results (P < 0.001).
Source
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun J. Sanyal et al. · Nature Medicine · 2024
DOI 10.1038/s41591-024-03018-2
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →